Vol. 4 No. 4 (2024)
Reimbursement Reviews

Olaparib (Lynparza)

decorative image of the issue cover

Published April 25, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses olaparib (Lynparza), 100 mg and 150 mg tablet, administered orally.
  • Indication: Olaparib is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before olaparib treatment is initiated.